Marinus Pharmaceuticals, Inc.

NasdaqGM:MRNS Stock Report

Market Cap: US$20.5m

Marinus Pharmaceuticals, Inc. Company Information

Marinus Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: Marinus Pharmaceuticals, Inc.
  • Ticker: MRNS
  • Exchange: NasdaqGM
  • Founded: 2003
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$20.496m
  • Shares Outstanding: 55.19m
  • Website: https://marinuspharma.com

Number of Employees

Location

  • Marinus Pharmaceuticals, Inc.
  • 5 Radnor Corporate Center
  • Suite 500
  • Radnor
  • Pennsylvania
  • 19087
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MRNSNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDAug 2014
61YDB (Deutsche Boerse AG)YesCommon StockDEEURAug 2014
MRNS *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNAug 2014
0JYLLSE (London Stock Exchange)YesCommon StockGBUSDAug 2014

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2024/12/30 18:44
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 18:44
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Marinus Pharmaceuticals, Inc. is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
François BriseboisCraig-Hallum Capital Group LLC
Douglas TsaoH.C. Wainwright & Co.